HIGHLIGHTS
- who: Maria Velegraki et al. from the Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James, Columbus, OH, USA have published the research: Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS, in the Journal: (JOURNAL)
- what: Unfortunately, the trial was prematurely terminated during the dosing escalation phase before reaching the planned maximum dose, as there were no observed hematological responses in other than one patient, who showed a noteworthy increase in their hemoglobin levels . The main reason for the failure of this trial seems to be . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.